Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 23, 2026 | $2.15 | +18.1% | $872.30M | +13.8% | $2.08 |
| Q1 FY26ended Mar 31, 2026 | Apr 23, 2026 | $1.92 | +56.1% | $844.90M | +21.0% | $1.68 |
| Q4 FY25ended Dec 31, 2025 | — | $1.82 | +2.8% | $805.00M | +7.5% | — |
| Q3 FY25ended Sep 30, 2025 | — | $1.92 | +3.8% | $804.60M | +7.7% | — |
| Q2 FY25ended Jun 30, 2025 | — | $1.82 | +20.5% | $766.50M | +9.2% | — |
| Q1 FY25ended Mar 31, 2025 | — | $1.23 | −20.6% | $698.00M | +0.4% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.77 | −3.3% | $748.80M | +2.3% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.85 | −13.6% | $746.90M |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe West Pharmaceutical Services shares, not any token. As of Jul 23, 2026, from Massive's standardised financials and the earnings calendar.
| −0.1% |
| — |
| Q2 FY24ended Jun 30, 2024 | — | $1.51 | — | $702.10M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $1.55 | — | $695.40M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $1.83 | — | $732.00M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $2.14 | — | $747.40M | — | — |